Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma

Sumit Isharwal(Memorial Sloan Kettering Cancer Center), Hikmat Al‐Ahmadie(Unknown), Victor E. Reuter(Memorial Sloan Kettering Cancer Center), Guido Dalbagni(Memorial Sloan Kettering Cancer Center), Samson W. Fine(Memorial Sloan Kettering Cancer Center), Kalyani Chadalavada(Memorial Sloan Kettering Cancer Center), François Audenet(Université Paris Cité), Satish K. Tickoo(Unknown), S. Machele Donat(Memorial Sloan Kettering Cancer Center), Hongying Huang(Memorial Sloan Kettering Cancer Center), Gouri J. Nanjangud(Memorial Sloan Kettering Cancer Center), Jonathan E. Rosenberg(Memorial Sloan Kettering Cancer Center), Gopa Iyer(Memorial Sloan Kettering Cancer Center), Dean F. Bajorin(Memorial Sloan Kettering Cancer Center), Byron Lee(Vanderbilt University Medical Center), Bernard H. Bochner(Memorial Sloan Kettering Cancer Center), David B. Solit(Memorial Sloan Kettering Cancer Center), Ying‐Bei Chen(Memorial Sloan Kettering Cancer Center), Harry W. Herr(Memorial Sloan Kettering Cancer Center), Anuradha Gopalan(Memorial Sloan Kettering Cancer Center)
Human Pathology
March 27, 2018
10.1016/j.humpath.2018.03.015
Cited by 51

Related Papers

Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Pan-cancer analysis of whole genomes
|Nature|2020|3.3k